Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
significant compared » significant component (Expand Search), significant impact (Expand Search), significant concern (Expand Search)
significant side » significant sex (Expand Search), significant burden (Expand Search), significant source (Expand Search)
Showing 1 - 20 results of 155 for search '(( significant decrease decrease ) OR ( ((significant compared) OR (significant side)) decrease ))~', query time: 0.55s Refine Results
  1. 1
    Analysis of Significantly Different Bacteria.

    Analysis of Significantly Different Bacteria. by Xu Jia (187142)

    Published 2025
    Save to List
    Saved in:
  2. 2
    Decreased clonogenic capacity of U87MG and U251MG GB cells following treatment with SHG-44 and cis-platin at equal concentrations.

    Decreased clonogenic capacity of U87MG and U251MG GB cells following treatment with SHG-44 and cis-platin at equal concentrations. by Denis Mustafov (19137870)

    Published 2025
    Save to List
    Saved in:
  3. 3
    Shares of antibiotic substances on total prescription in UTI treatment (N39.0, N30.0) by sex and age group in 2019 (female: n = 238.670 prescriptions; male: n = 40.641 prescriptions).

    Shares of antibiotic substances on total prescription in UTI treatment (N39.0, N30.0) by sex and age group in 2019 (female: n = 238.670 prescriptions; male: n = 40.641 prescription... by Thomas Hanslmeier (19949694)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  4. 4
    Shares of antibiotic substances on total prescription by quarter from 2013 to 2019 for female and male patients with UTI (N39.0, N30.0)(female: n = 1.681.255 prescriptions; male: n = 269.151prescriptions).

    Shares of antibiotic substances on total prescription by quarter from 2013 to 2019 for female and male patients with UTI (N39.0, N30.0)(female: n = 1.681.255 prescriptions; male: n... by Thomas Hanslmeier (19949694)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  5. 5
    Shares of specialist groups prescribing 1<sup>st</sup>, 2<sup>nd</sup>, and 3<sup>rd</sup> antibiotic prescriptions in UTI treatment of females (N39.0, N30.0) in 2018 and 2019.

    Shares of specialist groups prescribing 1<sup>st</sup>, 2<sup>nd</sup>, and 3<sup>rd</sup> antibiotic prescriptions in UTI treatment of females (N39.0, N30.0) in 2018 and 2019. by Thomas Hanslmeier (19949694)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  6. 6
    Number of antibiotic prescriptions in female and male patients with UTI (N30.0 and/or N39.0).

    Number of antibiotic prescriptions in female and male patients with UTI (N30.0 and/or N39.0). by Thomas Hanslmeier (19949694)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  7. 7
    Shares of antibiotic substances on total prescription in female patients with UTI (N39.0, N30.0) by physician specialties (GPs: n = 1.299.641 prescriptions; gynecologists n = 141.814 prescriptions; urologists n = 182.100 prescriptions).

    Shares of antibiotic substances on total prescription in female patients with UTI (N39.0, N30.0) by physician specialties (GPs: n = 1.299.641 prescriptions; gynecologists n = 141.8... by Thomas Hanslmeier (19949694)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  8. 8
    Comparison of 1<sup>st</sup>, 2<sup>nd</sup>, and 3<sup>rd</sup> antibiotic prescription.

    Comparison of 1<sup>st</sup>, 2<sup>nd</sup>, and 3<sup>rd</sup> antibiotic prescription. by Thomas Hanslmeier (19949694)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  9. 9
    UTI diagnoses by sex and physician specialty (2013–2019).

    UTI diagnoses by sex and physician specialty (2013–2019). by Thomas Hanslmeier (19949694)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  10. 10
    Stability differences between condition 1 and other conditions across participants on the non-hemiparetic side (NHP) side.

    Stability differences between condition 1 and other conditions across participants on the non-hemiparetic side (NHP) side. by Hyung Suk Yang (20442438)

    Published 2024
    Save to List
    Saved in:
  11. 11
    Fig 1 -

    Fig 1 - by Farshid Maleki (20521649)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 12
    Fig 8 -

    Fig 8 - by Farshid Maleki (20521649)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 13
    Schematic presentation of mechanism of anti-cancer activity of ATO and GCB combination in breast cancer cells.

    Schematic presentation of mechanism of anti-cancer activity of ATO and GCB combination in breast cancer cells. by Farshid Maleki (20521649)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 14
    Fig 4 -

    Fig 4 - by Farshid Maleki (20521649)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 15
    Fig 9 -

    Fig 9 - by Farshid Maleki (20521649)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 16
    Trypan blue dye exclusion assay for cell viability evaluation (% of control).

    Trypan blue dye exclusion assay for cell viability evaluation (% of control). by Farshid Maleki (20521649)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 17
    Fig 7 -

    Fig 7 - by Farshid Maleki (20521649)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 18
    Rate of apoptosis in MDA-MB-231 cells (ATO: 2.5 μM and GCB: 22.5 μM, 48 h, at 37°C).

    Rate of apoptosis in MDA-MB-231 cells (ATO: 2.5 μM and GCB: 22.5 μM, 48 h, at 37°C). by Farshid Maleki (20521649)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 19
    Fig 10 -

    Fig 10 - by Farshid Maleki (20521649)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 20
    Fig 5 -

    Fig 5 - by Farshid Maleki (20521649)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: